Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOT Biotech Acquisition	$10.15 -0.8%	$10.15	$8.30 ▼ $10.41	$291.81M	-0.12	244,605 shs	44,400 shs
DYN Dyne Therapeutics	$9.57 -4.8%	$11.83	$6.36 ▼ $47.45	$1.09B	1.17	1.76 million shs	4.65 million shs
INVA Innoviva	$19.96 -2.1%	$19.64	$16.18 ▼ $22.00	$1.25B	0.37	688,444 shs	3.00 million shs
LQDA Liquidia Technologies	$13.10 +2.1%	$15.22	$8.26 ▼ $19.41	$1.12B	0.04	1.23 million shs	2.09 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOT Biotech Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
DYN Dyne Therapeutics	0.00%	-7.27%	-19.04%	-8.51%	-72.88%
INVA Innoviva	0.00%	-4.95%	+1.63%	+10.09%	+21.71%
LQDA Liquidia Technologies	0.00%	-0.53%	-12.84%	-11.19%	+9.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIOT Biotech Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	3.6288 of 5 stars	4.5	3.0	0.0	0.0	2.5	3.3	0.0
INVA Innoviva	4.1142 of 5 stars	3.5	0.0	0.0	4.2	2.2	1.7	1.9
LQDA Liquidia Technologies	3.4281 of 5 stars	4.5	0.0	0.0	0.0	2.5	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIOT Biotech Acquisition	0.00	N/A	N/A	N/A
DYN Dyne Therapeutics	3.00	Buy	$41.13	329.73% Upside
INVA Innoviva	3.00	Buy	$55.00	175.55% Upside
LQDA Liquidia Technologies	3.00	Buy	$26.89	105.26% Upside

Current Analyst Ratings Breakdown

Latest BIOT, INVA, LQDA, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/25/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2025	DYN Dyne Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00
6/18/2025	DYN Dyne Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/18/2025	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$46.00 ➝ $32.00
6/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/12/2025	LQDA Liquidia Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$23.00 ➝ $25.00
6/11/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$37.00
6/11/2025	LQDA Liquidia Technologies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $23.00
6/2/2025	LQDA Liquidia Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$60.00 ➝ $34.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIOT Biotech Acquisition	N/A	N/A	N/A	N/A	($0.95) per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.19 per share	N/A
INVA Innoviva	$358.71M	3.49	$3.42 per share	5.83	$11.03 per share	1.81
LQDA Liquidia Technologies	$14M	79.99	N/A	N/A	$0.91 per share	14.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIOT Biotech Acquisition	-$6.86M	N/A	0.00	∞	N/A	N/A	-42.22%	3.48%	N/A
DYN Dyne Therapeutics	-$317.42M	-$3.59	N/A	N/A	N/A	N/A	-52.83%	-48.84%	8/11/2025 (Estimated)
INVA Innoviva	$23.39M	-$1.01	N/A	12.88	N/A	-16.15%	15.77%	8.41%	7/29/2025 (Estimated)
LQDA Liquidia Technologies	-$130.39M	-$1.58	N/A	N/A	N/A	-903.80%	-177.91%	-60.15%	8/6/2025 (Estimated)

Latest BIOT, INVA, LQDA, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	-$1.05	-$0.17	-$1.05	N/A	N/A
5/8/2025	Q1 2025	LQDA Liquidia Technologies	-$0.42	-$0.45	-$0.03	-$0.45	$3.23 million	$3.12 million
5/7/2025	Q1 2025	INVA Innoviva	N/A	$0.25	N/A	-$0.74	N/A	$88.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIOT Biotech Acquisition	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIOT Biotech Acquisition	N/A	0.03	0.03
DYN Dyne Therapeutics	N/A	20.35	20.35
INVA Innoviva	0.40	2.48	2.30
LQDA Liquidia Technologies	2.08	2.93	2.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIOT Biotech Acquisition	80.01%
DYN Dyne Therapeutics	96.68%
INVA Innoviva	99.12%
LQDA Liquidia Technologies	64.54%

Insider Ownership

Company	Insider Ownership
BIOT Biotech Acquisition	19.00%
DYN Dyne Therapeutics	20.77%
INVA Innoviva	2.25%
LQDA Liquidia Technologies	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIOT Biotech Acquisition	4	28.75 million	23.29 million	Not Optionable
DYN Dyne Therapeutics	100	113.67 million	90.06 million	Optionable
INVA Innoviva	100	62.78 million	61.36 million	Optionable
LQDA Liquidia Technologies	50	85.49 million	59.75 million	Optionable

BIOT, INVA, LQDA, and DYN Headlines

Recent News About These Companies

Liquidia Technologies (NASDAQ:LQDA) Trading Down 4.4% - What's Next?

June 25, 2025 | marketbeat.com

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

June 23, 2025 | finance.yahoo.com

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

June 23, 2025 | globenewswire.com

SG Americas Securities LLC Acquires New Holdings in Liquidia Technologies, Inc. (NASDAQ:LQDA)

June 19, 2025 | marketbeat.com

Liquidia Technologies, Inc. (NASDAQ:LQDA) Shares Bought by GAMMA Investing LLC

June 19, 2025 | marketbeat.com

Liquidia Technologies, Inc. (NASDAQ:LQDA) Sees Significant Growth in Short Interest

June 18, 2025 | marketbeat.com

Liquidia (NASDAQ:LQDA) Shares Up 3.1% on Analyst Upgrade

June 12, 2025 | marketbeat.com

Liquidia (NASDAQ:LQDA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

June 12, 2025 | marketbeat.com

Liquidia: Competitor Insmed's Stunning PAH Data Arrives At Precisely The Wrong Time

June 11, 2025 | seekingalpha.com

Liquidia (NASDAQ:LQDA) Given New $23.00 Price Target at Bank of America

June 11, 2025 | marketbeat.com

Liquidia (NASDAQ:LQDA) Shares Down 6.2% - Here's Why

June 11, 2025 | marketbeat.com

Liquidia (NASDAQ:LQDA) Shares Gap Down - Here's Why

June 10, 2025 | marketbeat.com

Stock Traders Purchase Large Volume of Liquidia Call Options (NASDAQ:LQDA)

June 10, 2025 | marketbeat.com

Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia

June 10, 2025 | msn.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 22,445 Shares of Liquidia Co. (NASDAQ:LQDA)

June 10, 2025 | marketbeat.com

Liquidia Co. (NASDAQ:LQDA) Receives Consensus Recommendation of "Buy" from Brokerages

June 10, 2025 | marketbeat.com

Millennium Management LLC Buys New Shares in Liquidia Co. (NASDAQ:LQDA)

June 9, 2025 | marketbeat.com

Liquidia (NASDAQ:LQDA) Shares Down 3.3% - What's Next?

June 4, 2025 | marketbeat.com

Liquidia (NASDAQ:LQDA) Stock Price Up 8.7% - Here's Why

June 4, 2025 | marketbeat.com

Liquidia Begins Commercial Rollout Of YUTREPIA For PAH And PH-ILD After FDA Approval

June 4, 2025 | nasdaq.com

Stocks To Watch: Liquidia Sees Relative Strength Rating Jump To 93

June 4, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

BIOT, INVA, LQDA, and DYN Company Descriptions

Biotech Acquisition NASDAQ:BIOT

Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Dyne Therapeutics NASDAQ:DYN

$9.57 -0.48 (-4.78%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.82 +0.24 (+2.56%)

As of 08:56 AM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Innoviva NASDAQ:INVA

$19.96 -0.43 (-2.11%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$20.57 +0.61 (+3.06%)

As of 09:22 AM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Liquidia Technologies NASDAQ:LQDA

$13.10 +0.27 (+2.10%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.10 +0.01 (+0.04%)

As of 09:25 AM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time